The molecular targets of approved treatments for pulmonary arterial hypertension
about
Guanylate cyclase stimulators for pulmonary hypertensionSwitching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human DiseasesCase report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variabilityFrom bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.Challenges and opportunities in treating inflammation associated with pulmonary hypertension.Selexipag for the treatment of pulmonary arterial hypertension.The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.A review of therapeutic agents for the management of pulmonary arterial hypertension.Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.Epidemiology and treatment of pulmonary arterial hypertension.Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension.First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.Prostanoid EP4 Agonist L-902,688 Activates PPARγ and Attenuates Pulmonary Arterial Hypertension.Targeting Pulmonary Endothelial Hemoglobin α Improves Nitric Oxide Signaling and Reverses Pulmonary Artery Endothelial Dysfunction.Meeting report of the 8th International Conference on cGMP "cGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017.Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).STIM2 (Stromal Interaction Molecule 2)-Mediated Increase in Resting Cytosolic Free Ca2+ Concentration Stimulates PASMC Proliferation in Pulmonary Arterial Hypertension.Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats.The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.Activation of GPER ameliorates experimental pulmonary hypertension in male rats.New targeted therapies in the treatment of pulmonary arterial hypertension: getting to the heart of the problem.[The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?]Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats.EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension.Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension.Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells
P2860
Q26470534-B89B8CCF-89C6-4841-84C5-D974A0CB5B03Q33812297-B0F2377E-664B-463C-97DE-238EC7B461B6Q33870122-8E63C0F1-C248-4956-8671-449166392ED6Q36021594-E637C0DA-EDC3-4075-AF6A-114072692518Q36382353-70A224C4-6A48-49B9-851C-FD2B3D42CF4DQ38612665-41E3DACC-35C2-4EFE-B9F6-5FDCFA0BB579Q38812727-71B637B8-C1A2-48D2-8F1B-6468F9E68C95Q38836877-3F186421-6A94-4121-8A23-0335A978AAECQ38841958-B52C71FE-B67B-41DD-9EF3-726CA60F472FQ38946618-DB28F83F-965F-4D46-B9FE-52312E772422Q39093828-8323650F-EFF4-4FCB-83FF-51E95B51F689Q39359218-14DE0FF9-B611-48C5-B98C-21135D8A150CQ42143771-6838446D-AE19-4EDC-AB9D-507E400FC299Q45960565-99CD3632-F027-4A57-9F15-125A536F54ABQ47110570-0095442A-00B9-4B4A-9C9A-793D24BE0C9AQ47394239-12711D3C-7427-4EB2-9420-85CE5C56BE53Q47698528-25ED1A51-BF6A-4B19-B654-4FA4E86CDE3CQ47904506-706E1452-B02F-44BE-BFDA-0428F41E0401Q48641553-6BE324E8-DB10-4221-8CF7-2D80FACA0192Q49544439-BE670259-4D81-4D39-AAF8-4FF55B87E822Q49873667-D25B2D2D-D752-48C8-8C96-892D1A63F216Q50416961-37DE21D6-E4BB-4E04-A045-590721DE9488Q50874649-F096FD2B-29AE-4761-BAEC-A85392FFF8F9Q51331393-9A850ED5-F0BD-4AD5-99B2-FB980B142D93Q51538305-8D2CAEF9-0903-4368-8410-2F63050D2C91Q52312423-840DF7FC-3CF3-4DA4-95CB-51605BB26BF0Q52574407-D1A4AE81-5815-47DF-946A-1A4CA8844C8DQ54935988-7F1A0414-E9D9-43CB-A845-91C1C0166C11Q55286186-F1E1458A-0AD1-4946-9CE7-793FD72A7797Q58178283-191D4D2F-DC04-44B3-9C8D-DC9040476BC5
P2860
The molecular targets of approved treatments for pulmonary arterial hypertension
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The molecular targets of approved treatments for pulmonary arterial hypertension
@ast
The molecular targets of approved treatments for pulmonary arterial hypertension
@en
The molecular targets of approved treatments for pulmonary arterial hypertension
@nl
type
label
The molecular targets of approved treatments for pulmonary arterial hypertension
@ast
The molecular targets of approved treatments for pulmonary arterial hypertension
@en
The molecular targets of approved treatments for pulmonary arterial hypertension
@nl
prefLabel
The molecular targets of approved treatments for pulmonary arterial hypertension
@ast
The molecular targets of approved treatments for pulmonary arterial hypertension
@en
The molecular targets of approved treatments for pulmonary arterial hypertension
@nl
P2860
P3181
P1433
P1476
The molecular targets of approved treatments for pulmonary arterial hypertension
@en
P2093
Hossein-Ardeschir Ghofrani
P2860
P3181
P356
10.1136/THORAXJNL-2015-207170
P407
P5008
P577
2015-07-28T00:00:00Z